Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing Enterobacterales

Among carbapenem-resistant Enterobacterales, metallo-beta-lactamase producing strains represent a growing therapeutic challenge. While the association of aztreonam and ceftazidime-avibactam has been investigated in recent years for the treatment of infections involving these strains, little to no cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Merad, Yanis, Conrad, Anne, Brosset, Sophie, Schmidt, Axel, Hanriat, Camille, Lustig, Sebastien, Laurent, Frederic, Kolenda, Camille, Roussel-Gaillard, Tiphaine, Batailler, Cecile, Ferry, Tristan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435880/
https://www.ncbi.nlm.nih.gov/pubmed/37601796
http://dx.doi.org/10.3389/fmed.2023.1224922
Descripción
Sumario:Among carbapenem-resistant Enterobacterales, metallo-beta-lactamase producing strains represent a growing therapeutic challenge. While the association of aztreonam and ceftazidime-avibactam has been investigated in recent years for the treatment of infections involving these strains, little to no clinical data support the use of this association for the treatment of bone and joint infections. We report two cases of complex bone and joint infections involving metallo-beta-lactamase-producing Enterobacterales, successfully treated at our referral center with aztreonam and ceftazidime-avibactam for 12 weeks in continuous infusions through elastomeric infusors.

Ejemplares similares